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Abstract 
 
We report a case of dislodged Levornogestrel-intrauterine system (LNG-IUS, Mirena®) without evidence of uterine 
perforation. A 37-year-old Para 4+1presented with 3 months history of lower abdominal pain. Examination and 
imaging showed that the device was not present in the uterine cavity. She underwent laparoscopic retrieval of 
Mirena®. There was no evidence of uterine perforation intra-operatively. This case illustrated the rare possibility of 
dislodged Mirena®intra-abdominally without evidence of uterine perforation. The management for missing IUS was 
reviewed. 
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Introduction 
 
Levonorgestrel-intrauterine system (LNG-IUS, 
Mirena®) was one of the most commonly used long-
acting reversible contraception. Its usage ranges 
widely from 2% to 80% in different countries (1), with 
83% of world users from Asia region (2). Mirena® 
being an effective contraception with reported Pearl 
Index of 0.15 and 0.22 through year 1 and 3 
respectively (3), had been recognised as an optimal 
treatment option for heavy menstrual bleeding and 
dysmenorrhea (1). However, the usage of Mirena® 
was not without its side effect or complication. We 
reported a case of dislodged Mirena® intra-
abdominally without evidence of uterine perforation 
and reviewed the option of management. 
 
Case Report 
 
A 37-year-old Para 4+1, presented to our centre with 
history of intermittent lower abdominal pain for the 
past 3 months requesting for Mirena® removal. She 
had Mirena® inserted in August 2014, 6 weeks post 
partum, by her family physician as contraception. She 
used the same contraceptive method prior to her last 
pregnancy. Soon after Mirena® insertion, she 
experienced some cramping abdominal discomfort, 
which was relieved by simple oral analgesia. Presence 
of Mirena® thread was confirmed for the first 3 
months as she had regular self-checking. 
Subsequently, she started experiencing irregular and 
prolonged vaginal bleeding with lower abdominal 
pain. She had no significant medical history. Her first 
delivery was via emergency lower segment caesarean 
section for poor progress, followed by complete 
miscarriage and 2 full term assisted vaginal deliveries. 
During speculum examination, Mirena® thread was 
not seen. Pelvic ultrasound revealed empty uterus with 
no evidence of Mirena® present in the uterine cavity. 
Computed tomography (CT) scan showed that the 
contraceptive device was located at the right pelvic 
cavity (Fig. 1). Diagnostic laparoscopy was performed 
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Figure 1: Non-enhanced CT scan of the pelvis in axial (a) 
and reformatted sagittal oblique (b). The T shape IUD is 
completely extra-uterine located anterolateral to the rectum 
(bent arrow) and postero-lateral to the uterus (star). The 
uterine outline is normal. 
 
 
 
Figure 2: Laparoscopy showed presence of LNG-IUS 
attached to the fimbriae end of right fallopian tube. 
 
performed. The device was found attached to the 
fimbriae end of right fallopian tube without any 
significant pelvic adhesion or evidence of uterine 
perforation (Fig. 2). She had an uneventful 
laparoscopic retrieval of the Mirena®. 
 
Discussion 
 
Continuous abdominal discomfort and irregular 
vaginal bleeding are the main reason for 
discontinuation of Mirena® use (4). The patient had 
lower abdominal discomfort and irregular vaginal 
bleeding for months after Mirena® insertion. She 
assumed those were side effects of Mirena® without 
any suspicious of her Mirena® being dislodged. Thus, 
she did not seek any treatment until her symptoms 
became unbearable and she requested for removal of 
Mirena®. 
 
A rare complication of Mirena® insertion was uterine 
perforation. The incidence of such complication 
ranged from 1.4-2.6 per 1000 insertion (5,6). 
Unfortunately, only 8.5% of the perforations were 
diagnosed at the time of insertion (7). Majority of 
patients (73%) were symptomatic with mild abdominal 
pain or abnormal vaginal bleeding (8). Asymptomatic 
patients were diagnosed mainly because of missing 
IUD threads or unintended pregnancy. Up to 75% of 
patients had onset of symptoms within 24 hours of 
insertion (8). As the side effects of Mirena® were 
similar to presentation of uterine perforation, thus the 
mean time taken from insertion to establishing the 
diagnosis was around 5 months (0-69 months) (8).  
 
Various imaging techniques had been used to locate 
the missing IUS with vaginal ultrasound being the 
most widely used modality. Other imaging includes 
abdominal radiography, hysteroscopy and CT scan 
(8,9). Besides that, Banerjee et al. described the use of 
fluoroscopy to help in localising the missing device 
when ultrasound, abdominal radiography and 
diagnostic laparoscopy failed to locate it (10). This 
patient had trans-vaginal ultrasound, which revealed 
absence of the device within the uterine cavity. CT 
scan was eventually performed and managed to locate 
the missing contraceptive device, which was situated 
in close proximity to the right fallopian tube. Unusual 
consequences after uterine perforation such as 
migration of Mirena® to the bladder (11) and small 
bowel obstruction (12) had been reported in the 
literature. Hence, imaging modalities are important 
pre-operative assessment tools that could assist in the 
planning of surgical retrieval.  
 
Majority of patients with missing IUS were managed 
surgically i.e. via laparoscopic route (8). Most of these 
missing devices were embedded within the omentum 
(65%) or within the pelvic cavity (35%). Surgical 
findings were usually unremarkable, as majority of 
these patients had no intra-abdominal adhesion (8). 
The patient had an uneventful laparoscopic retrieval of 
the missing IUS as there was only minimal adhesion 
noted between the device and the fimbrial end of right 
fallopian tube. Not surprisingly, there was no evidence 
of uterine perforation intra-operatively as the patient 
still managed to feel the thread 3 months after 
insertion. This raises the question: can Mirena® 
migrate through the fallopian tube to the abdominal 
cavity without uterine perforation? To date, there is no 
published report in the literature. Hence, this 
assumption is disputable.  
 
On the other hand, conservative management without 
surgical removal had also been reported in literature 
without much complication. Budiman et al. reported a 
39-year-old woman who became pregnant while on 
Mirena®. Caesarean section performed later found 
that the missing device was within the omentum (13). 
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Furthermore, Hopkins et al described a 6% risk of 
congenital anomalies in 35 pregnancies while using 
Mirena®; whereby 34 of these pregnancies were with 
intrauterine LNG-IUS and one with intraperitoneal 
LNG-IUS (14). Hence, conservative management 
could be an alternative option in selected cases. 
 
Conclusion  
 
It was crucial to be always on the lookout for 
possibility of complication even with simple 
procedures such as insertion of Mirena®. Thorough 
assessment and localisation of the missing intra-
uterine device with the help of imaging modalities are 
of paramount importance before any surgical 
intervention in order to minimise further morbidity and 
litigation. 
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